GlobeNewswire Inc.··Robbins LlpAldeyra Therapeutics Hit with Class Action Over Failed Drug; Stock Plummets 70%
Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.
ALDXclass action lawsuitlead plaintiff deadline